Phase I trial of fluorouracil modulation by N-phosphonacety-L-aspartate and 6-methylmercaptopurine riboside: Optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens

Journal of the National Cancer Institute

Volumn 83, Issue 17, 1991, Pages 1235-1240

  O'dwyer, Peter J ^a   Hudes, GaryR ^a   Colofiore, Joseph ^b   Walczak, Judy ^a   Hoffman, John ^a   Lacreta, Frank P ^a   Comis, Robert L ^a   Martin, Daniel S ^b   Ozols, Robert F ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b Catholic Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHYLTHIOINOSINE; FLUOROURACIL; SPARFOSIC ACID;

ARTICLE; BIOPSY; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; DRUG DOSE; DRUG INTERACTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MUCOSA INFLAMMATION; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SOLID TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARTIC ACID; BIOPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; DRUG INTERACTIONS; FEMALE; FLUOROURACIL; HUMAN; MALE; METHYLTHIOINOSINE; MIDDLE AGE; NEOPLASMS; PHOSPHONOACETIC ACID; PHOSPHORIBOSYL PYROPHOSPHATE; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025948221     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/83.17.1235     Document Type: Article

References (23)

1. Pinedo HM, Peters GF: Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 6:1653–1664, 1988
2. Leyland-Jones B, O’Dwyer PJ: Biochemical modulation: Application of laboratory models to the clinic. Cancer Treat Rep 70:219–229, 1986
3. Martin DS, Stolfi RL, Sawyer RC, et al: Application of biochemical modulation with a therapeutically inactive modulatory agent in clinical trials of cancer chemotherapy. Cancer Treat Rep 69:421–423, 1985
4. Santi DV, McHenry CS, Sommer H: Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 13:471–481, 1974
5. Grem JL, Hoth DF, Hamilton JM, et al: Overview of current status and future direction of clinical Urals with 5-fluorouracil in combination with folinic acid. Cancer Treat Rep 71:1249–1264, 1987
6. Coullns KD, Stark GR: Aspartate transcar-bamylase: Interaction with the transition state analogue N-(phosphonacetyl)-L-aspartate. J Biol Chem 246:6599–6605, 1971
7. Grem JL, King SA, O’Dwyer PJ, et al: Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: A review. Cancer Res 48:4441–4454, 1988
8. Martin DS, Stout RL, Sawyer RC, et al: Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: A murine study with clinical relevance. Cancer Res 43:2317–2321, 1983
9. Martin DS, Stolfi RL, Sawyer RC, et al: Improved therapeutic index with sequential N-phosphonacetyl-L-aspartate plus high-dose methotrexate plus high-dose 5-fluorouracil and appropriate rescue. Cancer Res 43:4653–4661, 1983
10. Casper ES, Vale K, Williams LJ, et al: Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluor-ouracil with N- (phosphonacetyl)-L-aspartic acid. Cancer Res 43:2324–2329, 1983
11. Ardalan B, Singh G, Silberman H: A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers. J Clin Oncol 6:1053–1058, 1988
12. O’Dwyer PJ, Paul AR, Walczak J, et al: Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. J Clin Oncol 8:1497–1503, 1990
13. Hurley MC, Lin B, Fox IH: Regulation of deoxyadenosine and nucleoside analog phosphorylation by human placental adenosine kinase. J Biol Chem 260:15675–15681, 1985
14. Bennett LL Jr, Brockman RW, Schnebli HP, et al: Activity and mechanism of action of 6-methylthiopurine ribonucleoside in cancer cells resistant to 6-mercaptopurine. Nature 205:1276–1279, 1965
15. Martin DS: Purine and pyrimidine biochemistry, and some relevant clinical and preclinical cancer chemotherapy research. In Metabolism and Action of Anticancer Drugs (Powis G, Prough RA, eds). London: Taylor & Francis, 1987, pp 91–140
16. Kufe DW, Egan EM: Enhancement of 5-fluorouracil incorporation into human lymphoblast ribonucleic acid. Biochem Pharmacol 30:129–133, 1981
17. Martin DS, Stolfi RL, Sawyer RC, et al; Biochemical modulation of 5-fluorouracil and cytosine arabinoside with emphasis on thymidine, PALA and 6-methylmercaptopurine riboside. In Nucleosides and Cancer Treatment (Tattersall NHN, Fox RM, eds). Sydney, Australia: Academic Press, 1981, pp 339–382
18. Martin DS, Stolfi RL, Sawyer RC, et al: An overview of thymidine. Cancer 45:1117–1128, 1980
19. Crabtree GW, Wiemann MC, Spremulli EN, et al: Phase I clinical trial of the combination of 6-methylmercaptopurirte riboside (MMPR) and 5-fluorouracil (5-FU). Proc ASCO 3:36, 1984
20. Peters WP, Weiss G, Kufe DW: Phase I trial of combination therapy with continuous-infusion MMPR and continuous-infusion 5-FU. Cancer Chemother Pharmacol 13:136–138, 1984
21. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207–214, 1981
22. Houghton JA, Tice AJ, Houghton PJ: The selectivity of action of methotrexate in combination with 5-fluorouracil in xenografts of human colon adenocarcinoma. Mol Pharmacol 22:771–778, 1982
23. Paterson AR, Wang MC: Mechanism of the growth inhibition potentiation arising from combination of 6-mercaptopurine with 6-(methylmercapto)purine ribonucleoside. Cancer Res 30:2379–2387, 1970